A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. Their results were conflicting, with one trial showing a significant easing of agitated behaviors in patients given a…
News
The Bluefield Project to Cure FTD will receive $1.2 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to validate an exploratory blood test in frontotemporal dementia (FTD). The award is the first FTD investment through the foundation’s Diagnostics Accelerator, a venture philanthropy vehicle to advance the development…
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow…
A newly opened Phase 2 clinical trial will test the sensitivity of new imaging tool for plaque buildup in the brains of people with mild cognitive impairment and dementia due to Alzheimer’s disease, Aprinoia Therapeutics announced. The trial is set to enroll 130 adults, 50 to 85 years old, a…
The Alzheimer’s Association and the African Methodist Episcopal Church (AME Church) announced a three-year partnership to promote greater involvement in the fight against Alzheimer’s (AD) and to heighten awareness of the support needed by patients and their families. Through the leadership of its International Health Commission, the…
The second part of a clinical study evaluating the use of a blood diagnostic test for Alzheimer’s disease — called the Lymphocyte Proliferation Test (LymPro Test) — is now fully enrolled, the trial’s sponsor, Breakthrough Diagnostics, announced. The trial is ongoing at Leipzig University in Germany, and top-line results…
The National Institutes of Health (NIH) has awarded the Alzheimer’s Association $1.34 million to find more evidence-based ways to enhance care and support for those with Alzheimer’s disease (AD) or other dementias, and their care partners. The five-year grant will support a project titled “Leveraging an Interdisciplinary Consortium…
A team led by a University of Washington (UW) School of Medicine scientist will use a $17.2 million National Institute on Aging (NIA) grant to study whether degenerative eye diseases are linked to Alzheimer’s disease (AD). The award went to Cecilia Lee, an assistant professor of ophthalmology. Along…
News
Antioxidant Compound, with Aid of Baker’s Yeast, May Offer Oral Supplement to Offset Alzheimer’s
A natural compound with antioxidative properties that might help to delay the onset of neurodegenerative diseases like Alzheimer’s can now be produced in baker’s yeast, a study reports. This new way of producing ergothioneine, as the compound is known, may lead to a commercially viable new treatment for people…
Expanding their existing relationship, Seniorlink and Humana are offering a program that provides additional care management and support to families caring for individuals with dementia, including Alzheimer’s disease. The dementia management program, which covers Humana Medicare Advantage members, capitalizes on Seniorlink’s experience and expertise in supporting caregivers. Specifically,…
Recent Posts
- FDA designation may speed new treatment for Alzheimer’s psychosis August 3, 2026
- Study reports Alzheimer’s treatment gains in long-term care July 6, 2026
- Awareness month event has new name: Do What You Love to End Alzheimer’s June 1, 2026
- FDA approves Auvelity to treat Alzheimer’s-related agitation May 4, 2026
- Daily Alzheimer’s pill slows brain shrinkage, boosts cognition April 6, 2026